| Factor Information | |
|---|---|
| Data ID | 2806 |
| Factor | Biochemical parameters: proBNP (pg/ml) |
| Description | After 6 months of therapy, an improvement in serology (pro-brain natriuretic peptide 303 ± 366 vs 760 ± 943 pg/ml; P=0.008) was observed. |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. |
| p Value | 0.008 |
| Conclusion | After 6 months of therapy, an improvement in serology (pro-brain natriuretic peptide 303 ± 366 vs 760 ± 943 pg/ml; P=0.008) was observed. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 625 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/ASD/AVC/SV |
| Reference | |
|---|---|
| PMID | 21081251 |
| Year | 2012 |
| Title | Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | a single-centre, open-label, single-arm, prospective study. | |
| Region | Naples, Italy | |
| Method | a single-centre, open-label, single-arm, prospective study. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | End of observation (patients after 6 months of bosentan–sildenafil combination therapy)(Treatment) | Basal(Control) |
| Number | 32 | 32(the same group) |
| Age | 37.1±13.7 years | N/A |
| Gender (Male: Female) | 14:18:00.000 | N/A |
| Marker Level | 303±366 pg/ml | 760±943 pg/ml |
